Forty years after the Nixon administration effectively shut down research on psychedelic drugs, Roland Griffiths helped reopen it. One of the nation’s leading psychopharmacologists, Griffiths’ research focuses on the behavioral and subjective effects of mood-altering drugs. He is the lead investigator of the Psilocybin Research Initiative at Johns Hopkins, which includes studies of psilocybin occasioned mystical experience in healthy volunteers and cancer patients, and a pilot study of psilocybin-facilitated smoking cessation. Roland is a Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine. He has been a consultant to the National Institutes of Health, and to numerous pharmaceutical companies in the development of new psychotropic drugs.